Do you want to read an article? Please log in or register.
Long-term safety of first-line osimertinib plus platinum-pemetrexed in EGFR-mutated advanced NSCLC: FLAURA2
Lung, Respiratory and Thoracic Cancer
Related content
Lung, Respiratory and Thoracic Cancer
Long-Term Benefit With First-Line Osimertinib Monotherapy in EGFR-Mutated Advanced NSCLC in the Era of Intensified First-Line Therapy
J Thorac Oncol
Ishida M, Yamada T, Yamaguchi O, Goto Y, Oba T, Shimamoto K, Tsuda T, Tanaka I, Shiraishi S, Furuya N, Yoshimura A, Mine K, Ota T, Hibino M, Kogure Y, Iwata T, Watanabe S, Tanaka H, Okimoto T, Sato I, Sasakura M, Nakashima K, Morita Y, Misono S, Ishizaki N, Tanimura K, Kawachi H, Nishioka N, Iwasaku M, Takayama K
doi: 10.1016/j.jtho.2026.106103
Lung, Respiratory and Thoracic Cancer
Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort study
Lung Cancer
Gomez-Randulfe I, Monaca F, Cantale O, Reale ML, Mrak L, Zullo L, Diaz SS, Bueno MZ, Maridueña Moreno MA, Davis C, Cox S, Lee D, Shah R, Geldart T, Baena J, Benitez JC, Rosario Garcia Campelo MA, Remon J, Planchard D, Galetta D, Tiseo M, Cortinovis D, Metro G, Bria E, Passiglia F, Novello S, Califano R
doi: 10.1016/j.lungcan.2025.108797
CHICAGO 2026
Lung, Respiratory and Thoracic Cancer
CHRYSALIS-2: First-line amivantamab plus lazertinib demonstrates durable OS in atypical EGFR-mutated advanced NSCLC
Lung, Respiratory and Thoracic Cancer
Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis
Lung Cancer
Hayashi H, Cho BC, Kim YJ, Lee SH, Danchaivijitr P, Alip A, Xiong H, How SH, Chang GC, Yang JC, Yamanaka Y, Nahit Şendur MA, Prabhash K, Azuma K, Akawung A, Fennema E, Tang X, Shah S, Sethi S, Lu S
doi: 10.1016/j.lungcan.2026.109305
Lung, Respiratory and Thoracic Cancer
Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC
Lung Cancer
Paz-Ares L, Veillon R, Majem M, Zhou C, Tang KJ, Kim SW, Richardson G, Girard N, Sanborn RE, Mansfield AS, Park K, Schuchard J, Diels J, Sermon J, Bhattacharya A, Lorenzini P, Wortman-Vayn H, Knoblauch RE, Agrawal T, Baig M, Ono A, Sabari JK
doi: 10.1016/j.lungcan.2025.108788
Lung, Respiratory and Thoracic Cancer
Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report
J Thorac Oncol
Hayashi H, Cho BC, Spigel DR, Girard N, Lee SH, Lu S, Popat S, Chih-Hsin Yang J, Passaro A, Baldotto C, Gottfried M, Dias JM, Zimmer Gelatti AC, Wang B, Kam J, Sethi S, Shah S, Kamat M, Zhang J, Curtin JC, William WN Jr, Besse B
doi: 10.1016/j.jtho.2026.103894
ESMO 2026
Lung, Respiratory and Thoracic Cancer
FLAURA-2: Early plasma EGFR mutation clearance is prognostic but not predictive of benefit from osimertinib plus chemotherapy
Lung, Respiratory and Thoracic Cancer
Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis
Lung Cancer
Zhou C, Tang KJ, Liu B, Kim SW, Kitazono S, Ono A, Thiagarajan M, Hung JY, Boyer M, Çİl T, Yao Y, Nagarkar R, Xie J, Bhattacharya A, Wortman-Vayn H, Baig M, Agrawal T, Lorenzini P, Lee SH, Cho BC
doi: 10.1016/j.lungcan.2026.109302
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Real-World Clinical Outcomes and Treatment Patterns in Advanced/Metastatic EGFR-Mutant NSCLC After Progression on First-Line Osimertinib for French Patients
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Adv Ther
Girard N, Macouillard P, Byng D, Meng J, Coerts F, Hunter S, Struebing A, Xiong Y, Park S, Haq MI, Tymejczyk O, Chouaid C, Audigier-Valette C, Debieuvre D, Quantin X, Bosquet L, Pérol M
doi: 10.1007/s12325-025-03465-4